InflaRx (IFRX) EBT Margin (2018 - 2026)
InflaRx (IFRX) posted EBT Margin of 428.52% for Q1 2026, up 477.44% sequentially from 74.21% in Q4 2025, and up 3513503.0% YoY from N/an in Q1 2025.
InflaRx (IFRX) EBT Margin (2018 - 2026) Analysis & Trends
InflaRx has reported EBT Margin for 9 years, with the latest figure at 428.52% in Q1 2026.
- Quarterly EBT Margin rose 3513503.0% year-over-year to 428.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.61% (up 1301.0% YoY) and the FY2025 annual result came in at 95.12%, down 823.0% from the prior year.
- EBT Margin advanced to 428.52% in Q1 2026 per IFRX's latest filing, from 74.21% in the prior quarter.
- Over five years, EBT Margin peaked at 1525.07% in Q1 2022 and troughed at 228994.05% in Q2 2024.
- A 5-year average of 22229.21% and a median of 0.22% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2025: EBT Margin tumbled 61301964 bps in 2022, then soared 19754974 bps in 2025.
- Over 5 years, EBT Margin stood at 4164.77% in 2022, then surged by 99 bps to 27.35% in 2023, then jumped by 404 bps to 83.04% in 2024, then dropped by 11 bps to 74.21% in 2025, then surged by 477 bps to 428.52% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 428.52%, 74.21%, and 37870.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn | -15,905.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 428.52% |
| Dec 31, 2025 | 74.21% |
| Sep 30, 2025 | -37,870.38% |
| Jun 30, 2025 | -31,444.31% |
| Mar 31, 2025 | -34,706.51% |
| Dec 31, 2024 | 83.04% |
| Sep 30, 2024 | -11,780.65% |
| Jun 30, 2024 | -228,994.05% |
| Mar 31, 2024 | -32,121.52% |
| Dec 31, 2023 | -27.35% |
| Sep 30, 2023 | -0.02% |
| Jun 30, 2023 | 528.02% |
| Mar 31, 2023 | -0.22% |
| Dec 31, 2022 | -4,164.77% |
| Sep 30, 2022 | 541.45% |
| Jun 30, 2022 | 32.81% |
| Mar 31, 2022 | 1,525.07% |
| Dec 31, 2021 | 608,854.87% |
| Sep 30, 2021 | 1,424.69% |
| Jun 30, 2021 | -115.92% |